相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Human Steroid Biosynthesis for the Oncologist
Mary Louise Auchus et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y. Loriot et al.
ANNALS OF ONCOLOGY (2013)
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
K. L. Noonan et al.
ANNALS OF ONCOLOGY (2013)
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
Robert H. Bradbury et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer
Masaki Shiota et al.
CANCER RESEARCH (2013)
PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era
Sean E. McGuire et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
Takahito Hara et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way
Sanjay N. Mediwala et al.
PROSTATE (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer
Sarah A. Loddick et al.
CANCER RESEARCH (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Juliet Richards et al.
CANCER RESEARCH (2012)
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
Masuo Yamaoka et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2012)
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J. Logothetis et al.
LANCET ONCOLOGY (2012)
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
Natasha M. DeVore et al.
NATURE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Steroid biosynthesis and prostate cancer
Nima Sharifi et al.
STEROIDS (2012)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Medha S. Darshan et al.
CANCER RESEARCH (2011)
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Dana Rathkopf et al.
CLINICAL CANCER RESEARCH (2011)
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Walter L. Miller et al.
ENDOCRINE REVIEWS (2011)
A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology
Rene Bruno et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
Yixian Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
William K. Oh et al.
UROLOGY (2011)
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease
Michael J. Donovan et al.
BJU INTERNATIONAL (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E
C. Andrieu et al.
ONCOGENE (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Gerhardt Attard et al.
CANCER CELL (2009)
Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
Ricardo M. Attar et al.
CANCER RESEARCH (2009)
Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
Kati K. Waltering et al.
CANCER RESEARCH (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Michel Bolla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Coactivator selective regulation of androgen receptor activity
Irina U. Agoulnik et al.
STEROIDS (2009)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
Kim N. Chi et al.
CLINICAL CANCER RESEARCH (2008)
Curcumin Blocks the Activation of Androgen and Interlukin-6 on Prostate-Specific Antigen Expression in Human Prostatic Carcinoma Cells
Ke-Hung Tsui et al.
JOURNAL OF ANDROLOGY (2008)
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
Adam Schayowitz et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
Tadas Vasaitis et al.
MOLECULAR CANCER THERAPEUTICS (2008)
CYP17 inhibition as a hormonal strategy for prostate cancer
Alison H. M. Reid et al.
NATURE CLINICAL PRACTICE UROLOGY (2008)
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity
Arnina Zoubeidi et al.
CANCER RESEARCH (2007)
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
M. Yoshimoto et al.
BRITISH JOURNAL OF CANCER (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells
Anthony J. Saporita et al.
PROSTATE (2007)
Ligand-specific dynamics of the androgen receptor at its response element in living cells
Tove I. Klokk et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Persistent intraprostatic androgen concentrations after medical castration in healthy men
Stephanie T. Page et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1;: Pten mice
Hui Gao et al.
CANCER RESEARCH (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Molecular chaperones throughout the life cycle of the androgen receptor
J Prescott et al.
CANCER LETTERS (2006)
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
S. Kumar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis
P Rocchi et al.
CANCER RESEARCH (2005)
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
G Attard et al.
BJU INTERNATIONAL (2005)
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
VD Handratta et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31
MV Pilepich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
C17,20-lyase inhibitors.: Part 2:: Design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-lyase inhibitors
N Matsunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Identification and validation of novel androgen-regulated genes in prostate cancer
AM Velasco et al.
ENDOCRINOLOGY (2004)
Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development
GR Cunha et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663
ME Taplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of novel 17α-hydroxylase/C17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo
S Haidar et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
Mechanism of antiandrogen action:: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor
V Georget et al.
BIOCHEMISTRY (2002)
Structural basis for the glucocorticoid response in a mutant human androgen receptor (ARccr) derived from an androgen-independent prostate cancer
PM Matias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
分享论文
